Bright Green Corp. engages in the cultivation, manufacture, and sale of medical cannabis. The company is headquartered in Fort Lauderdale, Florida and currently employs 5 full-time employees. The company went IPO on 2022-05-17. The firm specializes in the research, production, distribution, and advancement of plant-based drugs and APIs, including psilocybin, psilocyn, peyote, and opium poppy. The company plans to focus on the development of cannabis strains and sales of cannabis and hemp products with high contents of cannabinol (CBN) and cannabigerol (CBG). The company also plans to cultivate cannabis and focus on the production of dried flowers, and oils and marijuana extracts. In addition to cannabis, it also has a separate area for controlled substance cactus cultivation, and a separate controlled area for mushroom propagation. The company is in the process of completing construction of the 22-acre existing greenhouse to comply with the requirements for Schedule I and Schedule II plant-based drugs. The company also plans to construct two new 57-acre greenhouses, one each on the Candelaria property and Azuz property.